$ELVN

H.C. Wainwright raised its price target for Enliven Therapeutics (ELVN) to $73 from $65, maintaining a Buy rating. The stock is currently at $37.32, down 8.6% over the past week but up 142% year-to-date. The firm cited alignment with the FDA on the Phase 3 ENABLE-2 trial design for relcobatinib (ELVN-001) in chronic myeloid leukemia patients. Analysts expect positive trial results based on previous data. Other analysts also issued positive ratings and price targets for ELVN.

Enliven Therapeutics plans to initiate a Phase 3 trial of relcobatinib for chronic myeloid leukemia before year-end 2026. The company appointed Kristine Ball to its board, bringing extensive biotech experience. Enliven aims to commercialize relcobatinib, pending trial success and regulatory approval.

Enliven Therapeutics (ELVN) reported FDA alignment on the Phase 3 trial design for relcobatinib (ELVN-001) in treating chronic myeloid leukemia. This milestone indicates readiness for Phase 3 testing. According to the company, larger catalysts include trial initiation, enrollment progress, and positive results.

Garland J. Scott sold 13,000 shares of Enliven Therapeutics, Inc. (ELVN) at $46.67 ($0.61M total) on 2026-10-01.

JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.

Derynck Mika K sold 158,795 shares of Enliven Therapeutics, Inc. (ELVN) at $60.21 ($9.56M total) on 2026-08-04 under a Rule 10b5-1 trading plan.

Enliven Therapeutics, Inc. (ELVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignme

Biotech stocks hit 52-week highs on July 16, 2026 ahead of quarterly reports or a conference. CareDx (CDNA) rose to a 52-week high of $40.38% and reported Q1 revenue of $118M. Integra LifeSciences (IART) reached $20.26, with Q1 revenue $391.9M. Bioventus (BVS) hit $12.53, Q1 revenue $132M. Enliven Therapeutics (ELVN) hit $53.89 after a ~$460M public offering.

Kunkel Lori Anne sold 10,000 shares of Enliven Therapeutics, Inc. (ELVN) at an average of $50.49 ($49.98–$50.84, $0.50M total) across 2 trades on 2026-07-06 under a Rule 10b5-1 trading plan.

Enliven Therapeutics director Lori Anne Kunkel sold 10,000 shares for about $345,000 on June 5, 2026, per an SEC Form 4. The weighted average sale price was $34.54; she reduced her direct holdings by 16% to 51,884 shares. The sale followed a Rule 10b5-1 plan adopted March 6, 2026. Shares had risen 62.4% over the prior year.